Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors

@inproceedings{Wiedmann2012SafetyAE,
  title={Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors},
  author={Marcus W. Wiedmann and Joachim Moessner},
  booktitle={Clinical Medicine Insights. Oncology},
  year={2012}
}
Pancreatic neuroendocrine tumors (PNETs) are becoming increasingly common, with the majority of patients presenting with either lymph node involvement or metastatic disease, thus requiring systemic therapy. Targeted therapy is a type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth rather than by simply interfering with rapidly dividing cells (eg, with traditional chemotherapy). In this review article… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET)

  • A Vinik, E Van Cutsem, P Niccoli, al. et
  • J Clin Oncol
  • 2012

Similar Papers

Loading similar papers…